```html

Guillain‑Barré Syndrome (Weakness)

What is Guillain‑Barré syndrome (weakness)?

Guillain‑Barré syndrome (GBS) is an acute, immune‑mediated disorder of the peripheral nervous system. In most cases the immune system mistakenly attacks the myelin sheath that surrounds peripheral nerves, causing rapid‑onset muscle weakness, sensory changes, and sometimes paralysis. Weakness typically starts in the legs and spreads upward, but the pattern can vary. While the exact trigger is often unknown, GBS is considered a post‑infectious autoimmune reaction.

Although it can be frightening, the majority of patients survive with appropriate medical care. Early recognition and treatment are essential because the syndrome can progress quickly and affect breathing muscles.

Common Causes

GBS is not a single disease caused by one factor; rather, it is a reaction that may follow several different events. The most common precipitating conditions include:

• Respiratory infections – especially Campylobacter jejuni (a bacterial cause of gastroenteritis).
• Gastrointestinal infections – such as Salmonella, Shigella, or Escherichia coli.
• Viral infections – including influenza, Epstein‑Barr virus, cytomegalovirus, and Zika virus.
• Vaccinations – rare cases have been reported after influenza, hepatitis B, or COVID‑19 vaccines; the overall risk remains extremely low.
• Surgery – postoperative immune activation can trigger GBS in susceptible individuals.
• Autoimmune diseases – such as systemic lupus erythematosus or rheumatoid arthritis.
• HIV infection – GBS can appear during seroconversion or later in the disease course.
• Other neurological conditions – e.g., chronic inflammatory demyelinating polyneuropathy (CIDP) may evolve into an acute GBS picture.
• Environmental toxins – exposure to certain chemicals (e.g., organophosphates) has been linked in case reports.
• Genetic susceptibility – specific HLA types may increase risk, though this is not a modifiable cause.

Associated Symptoms

Weakness in GBS is seldom isolated. The following signs and symptoms frequently accompany the progressive loss of strength:

• Paresthesia – tingling, “pins‑and‑needles,” or numbness beginning in the feet and hands.
• Loss of reflexes – deep tendon reflexes (e.g., knee‑jerk) are often diminished or absent.
• Facial weakness – difficulty closing the eyes or making facial expressions; may include facial droop.
• Eye movement problems – double vision (diplopia) or difficulty moving the eyes (cranial nerve VI involvement).
• Autonomic dysfunction – abnormal heart rate, blood pressure swings, sweating, or bladder/bowel disturbances.
• Respiratory difficulties – shortness of breath, rapid breathing, or need for ventilatory support if the diaphragm is involved.
• Difficulty swallowing (dysphagia) or speaking (dysarthria).
• Pain – often described as aching or burning, especially in the back or limbs.

When to See a Doctor

GBS can progress from mild weakness to life‑threatening paralysis within days. Prompt medical evaluation is crucial if you notice any of the following:

• Sudden onset of weakness in the legs that spreads upward.
• Loss of reflexes or feeling “numb” in the feet or hands.
• Facial droop, difficulty closing one eye, or trouble swallowing.
• Rapidly worsening weakness that interferes with walking, climbing stairs, or rising from a chair.
• Shortness of breath, chest tightness, or a feeling that you cannot take a full breath.
• Severe, unexplained pain in the back or limbs.

Even if the symptoms seem mild, emergency department evaluation is warranted because early treatment (within the first 2‑4 weeks) improves outcomes.

Diagnosis

Diagnosing GBS is a clinical process supported by several tests:

1. Neurological Examination

• Assessment of muscle strength (Medical Research Council scale).
• Testing deep tendon reflexes, sensation, and cranial nerve function.
• Evaluation of autonomic signs (blood pressure, heart rate variability).

2. Lumbar Puncture (Spinal Fluid Analysis)

Typical findings include albuminocytologic dissociation: elevated protein with a normal white‑blood‑cell count. This pattern appears in ~70‑80 % of patients after the first week of symptoms.

3. Electrodiagnostic Studies

• Electromyography (EMG) – measures electrical activity of muscles.
• Nerve conduction studies (NCS) – assess speed and amplitude of signals; in GBS, conduction velocity is often slowed, and amplitudes reduced.

These studies help differentiate GBS subtypes (e.g., AIDP, AMAN, AMSAN) and rule out mimicking disorders.

4. Imaging

MRI of the spine may be performed to exclude spinal cord compression or transverse myelitis. Gadolinium‑enhanced MRI can show nerve root enhancement, supporting the diagnosis.

5. Laboratory Tests

Blood work is used to rule out other causes (e.g., diabetes, thyroid disease) and to identify possible triggers (e.g., recent infection, HIV test).

Treatment Options

The main goals of therapy are to halt immune attack, support vital functions, and promote recovery.

Immunotherapy

• Intravenous Immunoglobulin (IVIG) – 0.4 g/kg daily for 5 days. IVIG is as effective as plasma exchange and is easier to administer.
• Plasma Exchange (Plasmapheresis) – typically 4–6 exchanges over 1–2 weeks. It removes circulating antibodies and immune complexes.
• Both treatments are most beneficial when started within the first two weeks of symptom onset.

Supportive Care

• Respiratory monitoring – Frequent bedside spirometry; mechanical ventilation if vital capacity drops < 15 mL/kg.
• Cardiovascular monitoring – Continuous heart‑rate and blood‑pressure monitoring for autonomic instability.
• Pain management – NSAIDs, gabapentin, or duloxetine for neuropathic pain.
• Physical and occupational therapy – Early gentle range‑of‑motion exercises prevent contractures and aid recovery.
• Venous thromboembolism prophylaxis – Sequential compression devices or low‑dose anticoagulation if mobility is limited.

Home & Lifestyle Measures (after discharge)

• Gradual increase in activity under therapist guidance.
• Use of assistive devices (canes, walkers) until safe ambulation returns.
• Night‑time positioning to avoid pressure sores.
• Hydration and a balanced diet rich in protein to support nerve regeneration.
• Vaccinations (influenza, pneumococcal) after recovery, as infections can trigger relapse.

Prevention Tips

Because GBS is usually triggered by an infection, measures that reduce infection risk can lower the chance of developing the syndrome.

• Practice good hand hygiene and food safety to prevent Campylobacter and other gastrointestinal infections.
• Stay up‑to‑date with routine immunizations; the benefit far outweighs the minimal risk of GBS.
• Avoid unnecessary antibiotic use, which can disrupt gut flora and predispose to bacterial overgrowth.
• Seek prompt treatment for respiratory or gastrointestinal infections, especially in people with a personal or family history of autoimmune disease.
• Maintain a healthy immune system through adequate sleep, regular exercise, and balanced nutrition.

Emergency Warning Signs

---

Sources: Mayo Clinic, National Institute of Neurological Disorders and Stroke (NINDS), Centers for Disease Control and Prevention (CDC), Cleveland Clinic, WHO, and peer‑reviewed journals (Lancet Neurology 2022; JAMA Neurology 2021).

```